Announcements
- Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx lanceert Evkeeza® (evinacumab-concentraatoplossing voor infusie) in Nederland voor de behandeling van homozygote familiaire hypercholesterolemie (HoFH)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
- Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
- Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
More ▼
Key statistics
As of last trade, Ultragenyx Pharmaceutical Inc (UP0:DUS) traded at 37.20, 25.68% above the 52 week low of 29.60 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 37.40 |
---|---|
High | 37.40 |
Low | 37.20 |
Bid | 37.20 |
Offer | 37.80 |
Previous close | 37.20 |
Average volume | 10.67 |
---|---|
Shares outstanding | 83.13m |
Free float | 79.49m |
P/E (TTM) | -- |
Market cap | 3.34bn USD |
EPS (TTM) | -8.02 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 11:30 BST.
More ▼